-
2024-516392-33-00
5
2021-09-17
Patients (18-75 years) with metastatic and/or refractory soft-tissue
s
-
2024-511246-39-00
1
2021-07-27
Solid tumours with HER2 aberrations
-
2024-515229-26-00
5
2021-05-21
eosinophilic esophagitis
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2024-514014-13-00
9
2020-09-02
female and male adult patients with acute myeloid leukemia
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-514409-78-01
9
2019-07-26
relapsed / refractory or progressive high risk malignant disease
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2023-509318-13-00
6
2018-01-15
Multiple indications
-
2024-514556-32-00
5
2017-02-15
Adult critically ill patients with severe vitamin D deficiency
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2025-520488-42-00
4
2025-09-17
Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
-
2022-503001-38-01
5
2025-07-08
HR-positive HER-2- negative Breast Cancer
-
2024-513621-23-00
5
2025-04-18
Advanced/metastatic non-small cell lung cancer (NSCLC)
-
2023-510458-18-00
6
2025-03-11
Asthma
-
2022-502878-16-00
5
2025-01-23
Acute ischemic strokes with incomplete reperfusion
-
2023-504040-34-01
5
2024-11-12
Crohn’s Disease
-
2024-510753-10-00
5
2024-11-01
Prurigo Nodularis
-
2023-508096-36-00
5
2024-10-30
atopic dermatitis